AXOGEN, INC. (AXGN): what the price assumes

Generated: 2026-07-25 · Source: https://boothcheck.com/report/AXGN

Headline

Field	Value
Ticker	AXGN
Company	AXOGEN, INC.
Sector / Industry	Healthcare
Current price	$39.49/sh
Composition	U.S. 99% / International 1%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Field	Value
Inversion basis	revenue-multiple
EV / sales paid	9.2x
Steady-state operating margin assumed	29.7%
Must persist for	8.9y

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 10.7% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~1.9 years.

Reconcile: at the x-ray's 9.3% required return this reads ~6.3 years; the models below use their own rates.

How unusual the bet is: elevated

Reference	Value
vs own history	-0.54σ
sustained it ~8.9 years at this level	20%
implied end-window share	0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Family	Median price/FV	Models	Reads
Asset	8.78x	2	expensive
Earnings	14.15x	1	expensive
Relative	2.14x	3	expensive
Growth	2.80x	4	expensive

Families that call it expensive: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.1%); the inversion above states its own rate.

Per-Model Detail (n=10)

Model	Family	FV	Price/FV	Applicable	Methodology
DCF Perpetual Growth	Growth	$5.37	7.35x	yes	FCF base $0.0B, growth 22% (input: historical growth), terminal g 4.0%, WACC 9.1%, 7yr projection
DCF Exit Multiple	Growth	$27.00	1.46x	yes	Exit EV/EBITDA: 262.5x / 264.5x / 266.5x (bear / base = today's held flat / bull), 7yr
Relative Valuation	Relative	$18.46	2.14x	yes	P/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus
Simple DDM	Growth	—	—	no	—
Two-Stage DDM	Growth	—	—	no	—
Simple Excess Return	Asset	$4.75	8.31x	yes	Book value floor: BV/sh $4.75, ROE negative
Two-Stage Excess Return	Asset	$4.27	9.25x	yes	Book value with convergence: BV/sh $4.75, ROE converges to ke
Discounted Future Market Cap	Growth	$31.46	1.26x	yes	Rev $0.2B, growth 22% (input: historical growth; tapered), Terminal P/S: 6.9x / 8.6x / 10.2x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair Value	Relative	$0.00	—	no	Negative/zero EPS — earnings-based value floored at $0
Margin Trajectory	Growth	$9.53	4.14x	yes	Margin ramp: -13% → 12% over 7yr, rev growth 22% (input: historical growth; tapered)
Earnings Power Value	Earnings	—	—	no	—
Residual Income	Asset	—	—	no	—
Graham Number	Asset	—	—	no	—
EV/EBITDA Relative	Relative	$3.18	12.42x	yes	EBITDA $0.01B × sector EV/EBITDA 16.0x
FCF Yield	Earnings	$2.79	14.15x	yes	FCF $9.3M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF Yield	Earnings	—	—	no	—
Ben Graham Formula	Earnings	—	—	no	—
ROIC-Justified P/B	Asset	—	—	no	—
P/Sales Sector	Relative	$18.46	2.14x	yes	Revenue $0.24B × sector P/S 4.0x
PEG Fair Value	Relative	—	—	no	—
Earnings Yield	Earnings	—	—	no	—
Funds From Operations Multiple	Relative	—	—	no	—
Clinical Phase NPV	Growth	—	—	no	—
Merton	Asset	—	—	no	—
V5 Mechanical	—	—	—	no	—

Solvency

Field	Value
Net cash	$53.2m
Interest coverage	-0.1x
Share count CAGR (dilution)	5.4%
Burning cash	no

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Bullet Takeaways

• Avance became the first FDA-approved biologic for repairing gaps in peripheral nerves in December 2025, carrying twelve years of market exclusivity, which turns a product previously sold under tissue rules into one competitors cannot simply copy.
• That approval came through the accelerated pathway, and the 10-K is explicit that the indications "were granted under the FDA's accelerated approval program, and continued approval for these indications is contingent upon our timely completion of required post-marketing confirmatory studies".
• Management guided 2026 revenue to at least $265.7 million, a rise of at least 18%, and expects the year to turn free-cash-flow positive.

Bull Case

Run any standard valuation method across Axogen's trailing income statement and you get a small answer, because the trailing income statement describes a company that spent the last twelve months at roughly break-even on operations. That is a true description of the accounting and a poor description of the business. What the trailing figures do not encode happened on December 3, 2025, when the FDA approved Avance as a licensed biologic with twelve years of market exclusivity. The product being sold is the same. The legal position around it is not.

The distinction matters more than it sounds. Before approval, Avance was distributed as processed human tissue, a category where a competitor with comparable processing capability faces no approval barrier. As a licensed biologic it sits behind an exclusivity clock and a data package. The 10-K describes what that package had to contain: "Submission to the FDA of a BLA, which contains detailed information about the CMC for the product, reports of the outcomes and full data sets from the clinical trials, and proposed labeling and packaging for the product." The company frames the effort as "the transition of Avance Nerve Graft to a biological product, reflecting our dedication to both scientific advancement and regulatory excellence". Nobody undertakes that work for a product they expect to be commoditized.

Approval is also the key that unlocks the payer. Coverage has been the long-running constraint on nerve repair volumes, and it moved twice in short order. The 10-K notes that "Effective January 1, 2026, CMS created a new Ambulatory Payment Category 5433 for level 3 nerve repair. CPT 64912 was moved into this new code group, which further improves payment adequacy for advanced nerve repair." On the commercial side, management said more than 19.8 million additional U.S. lives gained coverage, lifting portfolio coverage above 65%. Surgeons do not adopt a repair technique the hospital will not be paid for. Removing that friction is worth more to volume than any amount of selling.

The unit economics behind the volume are unusually good for a business that processes donated tissue. Axogen keeps about 74% of revenue after the cost of producing the implants, which is territory normally occupied by devices rather than biologics manufacturing. The sales model is built to compound on that: the company grows first by deepening existing surgical accounts and second by adding new ones, backed by a commitment that "We expect the number of direct sales professionals to increase over time." It also names an indication most investors would not think of, describing how after a mastectomy "the nerves are cut to allow the removal of the breast tissue", leaving a sensation deficit a graft can address. That is a large, under-served population sitting adjacent to an existing surgical workflow.

Compare that against the cohort and the achievement reads more clearly. ATRC carries $552 million of revenue and still runs an operating margin of negative 0.5%; IRTC at $788 million runs negative 5.2%; GKOS at $551 million runs negative 36.1%. Reaching scale in surgical products does not automatically produce profit. Axogen is close to break-even on a revenue base a fraction of theirs, which says the incremental dollar is arriving with unusually little cost attached to it.

Bear Case

The variable with the most leverage on this story is not competition or manufacturing. It is who agrees to pay. The 10-K describes payers "designating these products investigational or experimental" and states plainly that "Some commercial payors do not currently cover or reimburse our products because they have determined insufficient evidence of favorable clinical outcomes is available." Management's own coverage figure implies roughly a third of commercially insured lives still sit outside the portfolio's coverage. Reimbursement policy is set by parties with an active financial interest in slowing adoption, moves on their timetable rather than the company's, and is the kind of exposure a revenue multiple this high does not naturally carry.

The regulatory win is also conditional rather than permanent. The filing states the indications "were granted under the FDA's accelerated approval program, and continued approval for these indications is contingent upon our timely completion of required post-marketing confirmatory studies", and elsewhere that "Continued approval for indications of sensory nerve discontinuities (>25mm) and for mixed and motor nerve discontinuities depends on verification and description of clinical benefit". Accelerated approval is a loan against future evidence. If the confirmatory work disappoints, the exclusivity the bull case rests on narrows at exactly the moment the commercial ramp needs it widest.

Against that sits what the price asks for. At roughly 9.2 times revenue, the market is assuming Axogen eventually earns an operating margin near 29.7% while growing at its self-funding ceiling for something like nine years. Trailing operations produced negative 0.4% instead. Only about 20% of comparable fast-growers kept that pace going for that long. And 29.7% is not a level this cohort reaches: PEN, the most profitable name in the group at $1.45 billion of revenue, converts 12.9% of it to operating profit; AORT manages 8.2% and INSP 5.6%. Axogen would need to become materially more profitable than any established peer, on a smaller base, and stay there. If it settles instead at the profitability the cohort actually demonstrates, the multiple the price rests on has no support underneath it.

Funding the ramp has cost holders their share of the company. The count is up about 5.4% a year since 2022. In January 2026 Axogen sold 4,600,000 shares, receiving net proceeds of 133.3 million dollars, and used them to retire and terminate its credit facility, which carried a rate the filing says "shall never be less than 9.5%". Swapping expensive borrowing for equity was the right call, and existing holders paid for it all the same. Production carries its own drag: the 10-K notes that after Axogen "commenced processing operations at the APC Facility", the associated challenges "have negatively impacted our gross margins", and supply itself depends on "supply agreements with recovery and acquisition agencies for peripheral nerve tissue". A biologic made from donated human tissue has an input constraint that no amount of demand can relax.

Valuation

Because Axogen does not yet earn a normal operating profit, the market cannot price it on earnings and prices it on sales instead. That lands the stock near 9.2 times revenue. Read backwards, that multiple embeds two assumptions at once: that the business eventually converts about 29.7% of revenue into operating profit, and that it keeps compounding at the fastest rate it can fund from its own cash for roughly nine years to get there. Over the trailing year the operating line converted negative 0.4% of revenue into profit, and the entire case rests on that distance closing.

The methods are unanimous about the distance, which is itself the finding. Value the company on its book, on its earnings power, on peer sales multiples, or on projected cash flows, and every one of those frames lands under the current price. There is no family here saying the price is defensible and another saying it is not; there is no disagreement to arbitrate. The price sits past the point where any standard frame reaches, which means the case for owning it cannot be built out of the trailing evidence at all. It has to be built out of the approval, the coverage expansion, and the assumption that the conversion to profit arrives on schedule.

On the growth half of that assumption the record is reassuring. The pace the price requires is close to what Axogen has actually been delivering, so the demand is not that the company accelerate; it is that it not decelerate for the better part of a decade. Only about one in five comparable fast-growers managed that. Converting revenue to profit is the harder half. Axogen keeps about 74% of revenue after the cost of producing the implants, which is the raw material for high profitability, but the distance from there to the bottom line is sales force, clinical work and the regulatory apparatus, and the filing is candid that its newer facility has weighed on production economics. The company describes recognizing revenue when it "transfers control of the products and services to the Company's customers" to "hospitals and surgical facilities for use in caring for patients with peripheral nerve damage or transection", which is to say the revenue is real and delivered, not booked against a pipeline. The question is only what fraction of it survives the trip to operating profit.

The balance sheet is no longer the constraint it was. Axogen paid off and terminated its credit facility in January 2026, funded by an offering of 4,600,000 shares, and management expects 2026 to be free-cash-flow positive. That removes the most obvious failure mode, a growth company forced to raise into weakness. What it does not remove is the arithmetic of the share count, which has risen about 5.4% a year since 2022. Every share issued to fund the ramp is a slice of the eventual 29.7% conversion the price is already paying for.

Catalysts

The defining event has already happened. On December 3, 2025 the FDA approved the Biologics License Application for Avance, making it the first and only approved biologic for repairing peripheral nerve discontinuities and granting twelve years of market exclusivity. The decision had earlier been pushed back by three months, so the approval also resolved a timing overhang. What follows from it is commercial rather than scientific: an approved biologic gives the sales organization something to take to payers that a tissue product never could.

The reimbursement machinery moved in step. Effective January 1, 2026, CMS created a new payment category for level 3 nerve repair and moved CPT 64912 into it, which the 10-K says "further improves payment adequacy for advanced nerve repair". On the commercial side, management reported more than 19.8 million additional U.S. lives gaining coverage during 2025, taking portfolio coverage above 65%, and set out a 2026 plan of at least 18% revenue growth to at least $265.7 million with the year turning free-cash-flow positive. Capacity to sell into that coverage is being added alongside it: 21 breast-focused representatives at year-end heading toward roughly 30, and 117 extremities representatives heading toward roughly 130.

The near-term tests are therefore about conversion rather than approval. Quarterly revenue against the at-least-18% path shows whether newly covered lives translate into procedures at the pace the guidance assumes, and the operating line shows whether the added sales headcount is being absorbed or is simply consuming the incremental gross profit. The post-marketing confirmatory studies that the accelerated approval depends on run in the background of both.

Peer Cohorts (Per Segment, With Filing Citations)

Peripheral Nerve Repair (reported)

• ATRC (AtriCure, Inc.)
• FY2025 10-K: …AtriClip FLEX-Mini device and EnCompass clamp meaningfully contributed to our growth in 2025. There are limited competitors in our key markets; however, new entrants are developing and marketing competing products, procedures, and/or clinical solutions that may cause variability in our results. Highlights of the…
• FY2025 10-K: …options for patients with Afib, including pharmacological therapy (anti-arrhythmic drugs) and implantable pacemakers. It is estimated that approximately 500,000 Afib patients are treated by catheter ablation every year in the United States, a number that is expected to see significant continued growth. While the…
• PRCT (PROCEPT BioRobotics Corporation)
• FY2025 10-K: …that growth in the use of surgical intervention over the past several years is due to the introduction of new technologies that better balance the compromise between efficacy and safety as well as growing awareness of surgical intervention as an effective way to manage BPH symptoms compared to drug therapy. There are…
• FY2025 10-K: …our robotic systems. We also plan to leverage our treatment data and software development capabilities to integrate artificial intelligence and machine learning to enable computer-assisted anatomy recognition and improved treatment planning and personalization. Our future growth is dependent on these continuous…
• IRTC (iRhythm Holdings, Inc.)
• FY2025 10-K: …the relevant payor or to the patient for the services rendered. If a patient fails to return a device, we experience financial losses, which include the cost of the device as well as the loss of potential revenue for the service that is contingent on the returned device for the submission of the associated claim. Our…
• FY2025 10-K: …which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device. After a device receives 510(k) clearance or PMA, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use,…
• INSP (Inspire Medical Systems, Inc.)
• FY2025 10-K: …condition and results of operations. In addition, if other companies are successful in developing neurostimulation devices that are approved for a broader range of indications than our Inspire system, we will be at a further competitive disadvantage, which could also affect our business, financial condition and…
• FY2025 10-K: …on our Inspire therapy. Our U.S. customers are generally reimbursed for the cost of patient treatment by various third-party payors, such as commercial insurance providers and Medicare. We have secured positive coverage policies with many U.S. commercial payors, including all large national commercial insurers,…
• ATEC (Alphatec Holdings, Inc.)
• FY2025 10-K: …reflect the Company's future ability to collect outstanding receivables or if the financial condition of customers were to deteriorate, resulting in impairment of their ability to make payments, an increase in the provision for doubtful accounts may be required. F- 12 Table of Contents The Company's accounts…
• FY2025 10-K: In addition, structural instability, abnormal motion, deformity, or mechanical failure of spinal elements can contribute to pain and functional impairment, either directly or by exacerbating neural compression. Spine surgery seeks to alleviate pain and restore function by addressing these underlying pathologies.…
• GKOS (GLAUKOS Corp)
• FY2025 10-K: …of corneal crosslinking therapies such as PeschkeTrade GmBH. Our anterior segment pipeline, if approved, would vastly expand our competition to numerous large companies such as AbbVie Inc., Alcon, Inc. and Johnson & Johnson, as well as some small companies that provide medical technology and pharmaceutical therapies…
• FY2025 10-K: …by five of the seven MACs, have disrupted traditional customer ordering patterns and may have resulted in certain of our customers' utilization of competitive products, which has reduced U.S. Glaucoma sales volumes of our iStent family of products used in conjunction with cataract surgery in each of the years ended…
• PEN (Penumbra, Inc)
• FY2025 10-K: …We implemented several proprietary design innovations to enable the coil to maintain shape while achieving biomechanically stable occlusion. Given the size and handling of Penumbra Coil 400, it is able to achieve higher packing density with fewer coils compared to competitive coiling systems. Penumbra SMART COIL is a…
• FY2025 10-K: …Catheters. Either Penumbra ENGINE or Penumbra Pump MAX is connected to our reperfusion catheters and provides the aspiration suction force. We developed our proprietary aspiration source as a fully-integrated system specifically for mechanical thrombectomy by aspiration. Embolization and Access Products Peripheral…
• AORT (ARTIVION, INC.)
• FY2025 10-K: …as adjustments to revenue, partially offset by an increase in PhotoFix and PerClot revenues. See Part II, Item 8, Note 11 of the "Notes to Consolidated Financial Statements" for further discussion regarding the Italian payback measure. Preservation Services Preservation services include service revenues from…
• FY2025 10-K: …mitral heart valves and the On-X ascending aortic prosthesis ("AAP") for heart valve replacement. Revenues from the sales of On-X products include revenues from the distribution of CarbonAid ® CO 2 diffusion catheters and from the sale of Chord-X ® ePTFE sutures for mitral chordal replacement. On-X product revenue…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Axogen press release, December 3, 2025 · Axogen Q4 2025 earnings call, February 24, 2026 · Axogen 10-K, long-term debt note, filed 2026 · FDA action-date extension reported November 2025